Literature DB >> 27177655

Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.

Amy K Erbe1, Wei Wang2, Mikayla Gallenberger2, Jacquelyn A Hank2, Paul M Sondel2,3.   

Abstract

Natural killer (NK) cells are one of the main effector immune cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC). Upon recognition of cell-bound IgG antibodies, which occurs through Fc gamma receptors (FCGRs) expressed on the cell surface of NK cells, NK cells become activated and lyse target tumor or infected cells. The FCGRs, FCGR3A and FCGR2C, expressed on the surface of NK cells have single nucleotide polymorphisms (SNPs) that result in differential activity of NK cells. In addition to SNP genetic variation within each of these genes, the FCGRs are subject to copy number variation (CNV), which leads to variable protein expression levels on the cell surface. Studies have found that FCGR genotype for FCGR3A and FCGR2C is associated with variation in the response to immunotherapy.Due to high sequence homology within FCGR3 and FCGR2 families, there are difficulties associated with genotyping these specific receptors related to cross-amplification of non-targeted FCGRs. To improve specificity for both FCGR3A and FCGR2C, Rnase-H (RH) primers were designed to amplify specifically FCGR3A (while not co-amplifying FCGR3B) and FCGR2C (while not co-amplifying FCGR2B). In addition, fluorescently labeled locked nucleic acid (LNA) probes provide additional precision for determination of the SNPs within both FCGR3A and FCGR2C. For CNV determination, separate fluorescently labeled probes for FCGR3A, and for FCGR2C, can be used with the same RH primers for each gene. These probes can be combined in the same well with control primers/probe for a known diploid gene and used to calculate the copy number of both FCGR3A and FCGR2C. Here we provide new detailed methodology that allows for the specific amplification of these FCGRs in a single PCR reaction, allowing for genotyping of both the SNPs and CNVs using real-time PCR.

Entities:  

Keywords:  ADCC; CNV; Cancer immunology; FCGR2C; FCGR3A; Immunotherapy; NK cells; SNP

Mesh:

Substances:

Year:  2016        PMID: 27177655      PMCID: PMC5476420          DOI: 10.1007/978-1-4939-3684-7_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

1.  Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers.

Authors:  David Latorra; Krista Campbell; Andreas Wolter; J Michael Hurley
Journal:  Hum Mutat       Date:  2003-07       Impact factor: 4.878

2.  Multiplex allele-specific PCR with optimized locked nucleic acid primers.

Authors:  David Latorra; Deborah Hopkins; Krista Campbell; J Michael Hurley
Journal:  Biotechniques       Date:  2003-06       Impact factor: 1.993

3.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

Authors:  Pierre Bruhns; Bruno Iannascoli; Patrick England; David A Mancardi; Nadine Fernandez; Sylvie Jorieux; Marc Daëron
Journal:  Blood       Date:  2008-11-18       Impact factor: 22.113

4.  A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B.

Authors:  Tahar van der Straaten; Richender Martijn; Toufik el Hajoui; Renee Baak-Pablo; Henk-Jan Guchelaar
Journal:  Pharmacogenet Genomics       Date:  2013-11       Impact factor: 2.089

Review 5.  Functional and clinical consequences of Fc receptor polymorphic and copy number variants.

Authors:  S Bournazos; J M Woof; S P Hart; I Dransfield
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

6.  Identification of the CD32/FcgammaRIIc-Q13/STP13 polymorphism using an allele-specific restriction enzyme digestion assay.

Authors:  D Metes; A A Gambotto; J Nellis; A Ruscin; A M Stewart-Akers; P A Morel; A S Rao
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

7.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Authors:  H R Koene; M Kleijer; J Algra; D Roos; A E von dem Borne; M de Haas
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

8.  Genomic organization of classical human low-affinity Fcgamma receptor genes.

Authors:  K Su; J Wu; J C Edberg; S E McKenzie; R P Kimberly
Journal:  Genes Immun       Date:  2002-10       Impact factor: 2.676

9.  RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers.

Authors:  Joseph R Dobosy; Scott D Rose; Kristin R Beltz; Susan M Rupp; Kristy M Powers; Mark A Behlke; Joseph A Walder
Journal:  BMC Biotechnol       Date:  2011-08-10       Impact factor: 2.563

10.  A comparison of assays for accurate copy number measurement of the low-affinity Fc gamma receptor genes FCGR3A and FCGR3B.

Authors:  Umi Shakina Haridan; Umairah Mokhtar; Lee R Machado; Abu Thalhah Abdul Aziz; Rafidah Hanim Shueb; Masliza Zaid; Benedict Sim; Mahiran Mustafa; Nik Khairudin Nik Yusof; Christopher K C Lee; Suhaili Abu Bakar; Sazaly AbuBakar; Edward J Hollox; Hoh Boon Peng
Journal:  PLoS One       Date:  2015-01-16       Impact factor: 3.240

View more
  3 in total

1.  FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Authors:  Amy K Erbe; Wei Wang; Jacob Goldberg; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; James W Mier; David J Panka; David F McDermott; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2016-10-14       Impact factor: 12.531

2.  An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages.

Authors:  Tae Hyun Kang; Chang-Han Lee; George Delidakis; Jiwon Jung; Odile Richard-Le Goff; Jiwon Lee; Jin Eyun Kim; Wissam Charab; Pierre Bruhns; George Georgiou
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

3.  Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1.

Authors:  Daniel I Chasman; Craig L Hyde; Franco Giulianini; Rebecca D Danning; Ellen Q Wang; Timothy Hickling; Paul M Ridker; A Katrina Loomis
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.